Wielka Brytania - angielski - VMD (Veterinary Medicines Directorate)

eu pharmaceuticals ltd - imidacloprid - spot-on solution - ectoparasiticide - cats, dogs, rabbits

Wielka Brytania - angielski - VMD (Veterinary Medicines Directorate)

eu pharmaceuticals ltd - imidacloprid - spot-on solution - ectoparasiticide - cats, dogs, rabbits

Wielka Brytania - angielski - VMD (Veterinary Medicines Directorate)

eu pharmaceuticals ltd - imidacloprid - spot-on solution - ectoparasiticide - cats, dogs, rabbits

Wielka Brytania - angielski - VMD (Veterinary Medicines Directorate)

eu pharmaceuticals ltd - imidacloprid - spot-on solution - ectoparasiticide - cats, dogs, rabbits

Wielka Brytania - angielski - VMD (Veterinary Medicines Directorate)

eu pharmaceuticals ltd - imidacloprid - spot-on solution - ectoparasiticide - cats, dogs, rabbits

Wielka Brytania - angielski - VMD (Veterinary Medicines Directorate)

eu pharmaceuticals ltd - imidacloprid - spot-on solution - ectoparasiticide - cats, dogs, rabbits

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

professional complementary health formulas - calendula officinalis 6x rhododendron chrysanthum 6x ruta graveolens 6x lithium carbonicum 12x cartilage 12x, 30x ligament 12x, 30x ammonium phosphoricum 12x, 30x, 100x hypericum perforatum 30x natrum sulphuricum 30x nux vomica 30x - for the temporary relief of minor joint pain or inflammation, particularly in the fingers or toes.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - erlotinib hydrochloride, quantity: 109.27 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - non-small cell lung cancer erlotinib sandoz is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations.,erlotinib sandoz is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfrmutations who have not progressed on first-line chemotherapy.,erlotinib sandoz is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib sandoz in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - erlotinib hydrochloride, quantity: 27.32 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - non-small cell lung cancer erlotinib sandoz is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations.,erlotinib sandoz is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfrmutations who have not progressed on first-line chemotherapy.,erlotinib sandoz is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib sandoz in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - erlotinib hydrochloride, quantity: 163.9 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - non-small cell lung cancer erlotinib sandoz is indicated for the first-line treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations.,erlotinib sandoz is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfrmutations who have not progressed on first-line chemotherapy.,erlotinib sandoz is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.,pancreatic cancer erlotinib sandoz in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.